insulin aspart vs Insulin lispro (Lyumjev)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline
insulin aspart · NovoLog
Marketed by Novo Nordisk
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2028 · NCT07652528 (registry estimate)
No aligned efficacy figure on record for this race.
Insulin lispro (Lyumjev)
Marketed by Eli Lilly
NCT03214380 · Phase 3 · completed
The study randomized and double-blinded participants to LY900014 or insulin lispro, with 933 enrolled and approximately 336-337 participants in the main comparison arms. The primary HbA1c endpoint met the prespecified non-inferiority margin, but HbA1c is a laboratory surrogate rather than a hard clinical endpoint, supporting a moderate evidence grade.
Reported efficacy
Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): LY900014 -0.56 Percentage of HbA1c (Standard Error 0.046) vs Insulin Lispro (Humalog) -0.63 Percentage of HbA1c (Standard Error 0.061) (met)
Result source: NCT03952143
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | insulin aspart | Insulin lispro (Lyumjev) |
|---|---|---|
| HbA1c, change | -1.2% vs -1.2%vs Insulin GlargineNCT0488085019 other results
| -0.4% vs -0.4%vs Insulin Lispro (Humalog)NCT032143801 other result
|
| Body weight, change (kg) | 2.7 vs 2.2vs Insulin GlargineNCT0488085011 other results
| —Not reported |
| HbA1c below 7% | 44% vs 20%vs Metformin, Insulin Detemir, Insulin AspartNCT01966978 | —Not reported |
| Fasting plasma glucose, change | -1.8 vs -1.6vs Insulin GlargineNCT048808505 other results
| —Not reported |
| 3-point MACE (% with event) | —Not posted · NCT01467323 | —Not reported |
HbA1c, change
- insulin aspart
- -1.2% vs -1.2%vs Insulin GlargineNCT04880850
19 other results
- -1.5% vs -1.4% NCT02762578
- -1.9% vs -1.7% NCT01513590
- -1.4% vs -1.4% NCT01059812
- -1.6% vs -1.7% NCT01045707
- -1.2% vs -1.3% NCT00972283
- -0.7% vs 0.1% NCT01388361
- -1.4% vs -1.2% NCT01272193
- -1.0% vs -1% NCT01045447
- -1.3% vs -1.3% NCT01009580
- -1.1% vs -1.1% NCT02648217
- -1.4% vs -1.3% NCT01045707
- -0.9% vs -1.1% NCT00972283
- -1.2% vs -1.3% NCT02453685
- -1.0% vs -1.1% NCT01165684
- -0.5% vs 0% NCT04538352
- 4.1% vs 3.4% NCT01966978
- -0.5% vs -0.5% NCT01194258
- -0.8% vs -1.1% NCT01165684
- -0.5% vs -1% NCT01165684
- Insulin lispro (Lyumjev)
- -0.4% vs -0.4%vs Insulin Lispro (Humalog)NCT03214380
1 other result
- -0.6% vs -0.6% NCT03952143
Body weight, change (kg)
- insulin aspart
- 2.7 vs 2.2vs Insulin GlargineNCT04880850
11 other results
- 2.8 vs 2.2 NCT02762578
- 2.8 vs 2 NCT01513590
- -1 vs 0.1 NCT01388361
- 0.7 vs 0.7 NCT01272193
- 1.1 vs 1.4 NCT01059812
- 0.9 vs 0.3 NCT01474538
- -8.6 vs 1.4 NCT04538352
- -0.6 vs 3.1 NCT01966978
- 1.5 vs 1.6 NCT01194258
- 0.3 vs 0.8 NCT00998335
- 0.1 vs -0.1 NCT00842361
- Insulin lispro (Lyumjev)
- —Not reported
HbA1c below 7%
- insulin aspart
- 44% vs 20%vs Metformin, Insulin Detemir, Insulin AspartNCT01966978
- Insulin lispro (Lyumjev)
- —Not reported
Fasting plasma glucose, change
- insulin aspart
- -1.8 vs -1.6vs Insulin GlargineNCT04880850
5 other results
- -3.0 vs -1.6 NCT02762578
- -4.4 vs -3.0 NCT01513590
- -0.1 vs -1.2 NCT01388361
- -2 vs -4.4 NCT02648217
- 6.4 vs 4.9 NCT00998335
- Insulin lispro (Lyumjev)
- —Not reported
3-point MACE (% with event)
- insulin aspart
- —Not posted · NCT01467323
- Insulin lispro (Lyumjev)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. insulin aspart: 5 of 5 rows · Insulin lispro (Lyumjev): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | insulin aspart Rows use multiple source trials | Insulin lispro (Lyumjev) Rows use multiple source trials |
|---|---|---|
| HbA1c absolute change · percentage points No placebo or comparator arm | -1.45% (n=136) @ 26wka,b,c,d NCT01680341 · Phase 3 · registry result, not featured evidence show 1 more dose-1.33% (n=136) @ 26wk NCT01680341 · Phase 3 · registry result, not featured evidence | -0.44% (n=167) @ 12wkb,c,d NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3 |
| Dropout rate | 0%once weeklye NCT04538352 · Phase 4 · registry result, not featured evidence · combination show 24 more results22% NCT01966978 · Phase 4 · registry result, not featured evidence · combination 11.3% NCT02453685 · Phase 4 · registry result, not featured evidence 13.9% NCT01165684 · Phase 4 · registry result, not featured evidence — NCT00998335 · Phase 4 · registry result, not featured evidence · combination 0% NCT00591227 · Phase 4 · registry result, not featured evidence 5.5% NCT04880850 · Phase 3 · registry result, not featured evidence 2.2% NCT02906917 · Phase 3 · registry result, not featured evidence 4.2%BID NCT02762578 · Phase 3 · registry result, not featured evidence 7.6%twice daily NCT02648217 · Phase 3 · registry result, not featured evidence 15.4%IDegAsp Simple NCT01680341 · Phase 3 · registry result, not featured evidence 12.5%IDegAsp Step Wise NCT01680341 · Phase 3 · registry result, not featured evidence — NCT01474538 · Phase 3 · registry result, not featured evidence 5.1% NCT01513590 · Phase 3 · registry result, not featured evidence 13.6% NCT01388361 · Phase 3 · registry result, not featured evidence · combination 6.6%IDegAsp Simple NCT01365507 · Phase 3 · registry result, not featured evidence 6.4%IDegAsp Step Wise NCT01365507 · Phase 3 · registry result, not featured evidence 6.8%OD NCT01272193 · Phase 3 · registry result, not featured evidence 13.1%BID NCT01059812 · Phase 3 · registry result, not featured evidence 18.1%once daily NCT00972283 · Phase 3 · registry result, not featured evidence 15.5%once daily NCT01045447 · Phase 3 · registry result, not featured evidence 17.7% NCT01045707 · Phase 3 · registry result, not featured evidence 12.1% NCT01009580 · Phase 3 · registry result, not featured evidence — NCT01194258 · Phase 2 · registry result, not featured evidence 3% NCT00842361 · Phase 2 · registry result, not featured evidence | —f NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 16 more results— NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3 17.6% NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3 —LY900014 After Meal NCT03341312 · Phase 1 · registry result, not featured evidence —LY900014 Before Meal NCT03341312 · Phase 1 · registry result, not featured evidence —15 U NCT03286751 · Phase 1 · registry result, not featured evidence —30 U NCT03286751 · Phase 1 · registry result, not featured evidence —7 U NCT03286751 · Phase 1 · registry result, not featured evidence —15 U NCT03305822 · Phase 1 · registry result, not featured evidence —15 U NCT03232983 · Phase 1 · registry result, not featured evidence —15 U NCT03232983 · Phase 1 · registry result, not featured evidence —15 U NCT03232983 · Phase 1 · registry result, not featured evidence —15 U NCT03232983 · Phase 1 · registry result, not featured evidence —LY900014 - Test (Part B) NCT02703337 · Phase 1 · registry result, not featured evidence —LY900014 - Test +15 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence · combination —LY900014 - Test -15 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence —LY900014 - Test 0 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —once weeklye NCT04538352 · Phase 4 · registry result, not featured evidence · combination show 24 more results— NCT01966978 · Phase 4 · registry result, not featured evidence · combination 0% NCT02453685 · Phase 4 · registry result, not featured evidence 0.5% NCT01165684 · Phase 4 · registry result, not featured evidence — NCT00998335 · Phase 4 · registry result, not featured evidence · combination — NCT00591227 · Phase 4 · registry result, not featured evidence — NCT04880850 · Phase 3 · registry result, not featured evidence 0.4% NCT02906917 · Phase 3 · registry result, not featured evidence 0.3%BID NCT02762578 · Phase 3 · registry result, not featured evidence 0%twice daily NCT02648217 · Phase 3 · registry result, not featured evidence 2.2%IDegAsp Simple NCT01680341 · Phase 3 · registry result, not featured evidence 1.5%IDegAsp Step Wise NCT01680341 · Phase 3 · registry result, not featured evidence — NCT01474538 · Phase 3 · registry result, not featured evidence 1% NCT01513590 · Phase 3 · registry result, not featured evidence 5.7% NCT01388361 · Phase 3 · registry result, not featured evidence · combination —IDegAsp Simple NCT01365507 · Phase 3 · registry result, not featured evidence —IDegAsp Step Wise NCT01365507 · Phase 3 · registry result, not featured evidence 0.7%OD NCT01272193 · Phase 3 · registry result, not featured evidence 3.2%BID NCT01059812 · Phase 3 · registry result, not featured evidence 4.1%once daily NCT00972283 · Phase 3 · registry result, not featured evidence 0%once daily NCT01045447 · Phase 3 · registry result, not featured evidence 1.9% NCT01045707 · Phase 3 · registry result, not featured evidence 1.8% NCT01009580 · Phase 3 · registry result, not featured evidence — NCT01194258 · Phase 2 · registry result, not featured evidence — NCT00842361 · Phase 2 · registry result, not featured evidence | —f NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 16 more results— NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.7% NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3 —LY900014 After Meal NCT03341312 · Phase 1 · registry result, not featured evidence —LY900014 Before Meal NCT03341312 · Phase 1 · registry result, not featured evidence —15 U NCT03286751 · Phase 1 · registry result, not featured evidence —30 U NCT03286751 · Phase 1 · registry result, not featured evidence —7 U NCT03286751 · Phase 1 · registry result, not featured evidence —15 U NCT03305822 · Phase 1 · registry result, not featured evidence —15 U NCT03232983 · Phase 1 · registry result, not featured evidence —15 U NCT03232983 · Phase 1 · registry result, not featured evidence —15 U NCT03232983 · Phase 1 · registry result, not featured evidence —15 U NCT03232983 · Phase 1 · registry result, not featured evidence —LY900014 - Test (Part B) NCT02703337 · Phase 1 · registry result, not featured evidence —LY900014 - Test +15 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence · combination —LY900014 - Test -15 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence —LY900014 - Test 0 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 22.5%once weeklye NCT04538352 · Phase 4 · registry result, not featured evidence · combination show 24 more results11.1% NCT01966978 · Phase 4 · registry result, not featured evidence · combination 8.4% NCT02453685 · Phase 4 · registry result, not featured evidence 9.1% NCT01165684 · Phase 4 · registry result, not featured evidence 0% NCT00998335 · Phase 4 · registry result, not featured evidence · combination 0% NCT00591227 · Phase 4 · registry result, not featured evidence 7.6% NCT04880850 · Phase 3 · registry result, not featured evidence 6.8% NCT02906917 · Phase 3 · registry result, not featured evidence 4.4%BID NCT02762578 · Phase 3 · registry result, not featured evidence 3.8%twice daily NCT02648217 · Phase 3 · registry result, not featured evidence 5.2%IDegAsp Simple NCT01680341 · Phase 3 · registry result, not featured evidence 7.5%IDegAsp Step Wise NCT01680341 · Phase 3 · registry result, not featured evidence 11.8% NCT01474538 · Phase 3 · registry result, not featured evidence 6.6% NCT01513590 · Phase 3 · registry result, not featured evidence 4.6% NCT01388361 · Phase 3 · registry result, not featured evidence · combination 0.7%IDegAsp Simple NCT01365507 · Phase 3 · registry result, not featured evidence 4.3%IDegAsp Step Wise NCT01365507 · Phase 3 · registry result, not featured evidence 3.4%OD NCT01272193 · Phase 3 · registry result, not featured evidence 8.2%BID NCT01059812 · Phase 3 · registry result, not featured evidence 18.5%once daily NCT00972283 · Phase 3 · registry result, not featured evidence 4.3%once daily NCT01045447 · Phase 3 · registry result, not featured evidence 11.3% NCT01045707 · Phase 3 · registry result, not featured evidence 8.5% NCT01009580 · Phase 3 · registry result, not featured evidence 6.5% NCT01194258 · Phase 2 · registry result, not featured evidence 3% NCT00842361 · Phase 2 · registry result, not featured evidence | 7.7%f NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 16 more results8.4% NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.7% NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3 0%LY900014 After Meal NCT03341312 · Phase 1 · registry result, not featured evidence 0%LY900014 Before Meal NCT03341312 · Phase 1 · registry result, not featured evidence 0%15 U NCT03286751 · Phase 1 · registry result, not featured evidence 0%30 U NCT03286751 · Phase 1 · registry result, not featured evidence 0%7 U NCT03286751 · Phase 1 · registry result, not featured evidence 0%15 U NCT03305822 · Phase 1 · registry result, not featured evidence 0%15 U NCT03232983 · Phase 1 · registry result, not featured evidence 0%15 U NCT03232983 · Phase 1 · registry result, not featured evidence 0%15 U NCT03232983 · Phase 1 · registry result, not featured evidence 0%15 U NCT03232983 · Phase 1 · registry result, not featured evidence 0%LY900014 - Test (Part B) NCT02703337 · Phase 1 · registry result, not featured evidence 0%LY900014 - Test +15 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence · combination 0%LY900014 - Test -15 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence 0%LY900014 - Test 0 Min (Part A) NCT02703337 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | once weeklye pain 17.5% upper respiratory infection 0% NCT04538352 · Phase 4 · registry result, not featured evidence · combination show 22 more resultsgi 77.8% headache 25.9% other ae 7.4% NCT01966978 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 12.7% headache 7.2% arthralgia 6.6% NCT02453685 · Phase 4 · registry result, not featured evidence nasopharyngitis 8.1% headache 5.1% influenza 5.1% NCT01165684 · Phase 4 · registry result, not featured evidence covid-19 8.6% diarrhoea 5.2% diabetic retinopathy 4.1% NCT04880850 · Phase 3 · registry result, not featured evidence nasopharyngitis 13.6% headache 10.2% back pain 6% NCT02906917 · Phase 3 · registry result, not featured evidence BID upper respiratory tract infection 21.1% diabetic retinopathy 10% viral upper respiratory tract infection 2.5% NCT02762578 · Phase 3 · registry result, not featured evidence twice daily blood glucose decreased 35.4% upper respiratory tract infection 6.2% pyrexia 3.1% NCT02648217 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 10.4% nasopharyngitis 8.9% headache 6.7% NCT01680341 · Phase 3 · registry result, not featured evidence nasopharyngitis 14.9% influenza 9% upper respiratory tract infection 7.5% NCT01680341 · Phase 3 · registry result, not featured evidence nasopharyngitis 4.2% rhinitis allergic 4.2% back pain 3.4% NCT01474538 · Phase 3 · registry result, not featured evidence nasopharyngitis 7.7% NCT01513590 · Phase 3 · registry result, not featured evidence nausea 20.7% diarrhoea 10.3% nasopharyngitis 10.3% NCT01388361 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 9% nasopharyngitis 6% NCT01365507 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 10.7% nasopharyngitis 7.9% NCT01365507 · Phase 3 · registry result, not featured evidence OD nasopharyngitis 22.4% diabetic retinopathy 5.4% NCT01272193 · Phase 3 · registry result, not featured evidence BID nasopharyngitis 18.3% upper respiratory tract infection 7.5% diabetic retinopathy 6.8% NCT01059812 · Phase 3 · registry result, not featured evidence once daily nasopharyngitis 16.5% upper respiratory tract infection 16.3% headache 9.4% NCT00972283 · Phase 3 · registry result, not featured evidence once daily headache 8.7% nasopharyngitis 7.4% diarrhoea 5.2% NCT01045447 · Phase 3 · registry result, not featured evidence nasopharyngitis 13.6% hypertension 7.5% back pain 6% NCT01045707 · Phase 3 · registry result, not featured evidence nasopharyngitis 11.6% upper respiratory tract infection 7.6% headache 5.8% NCT01009580 · Phase 3 · registry result, not featured evidence uterine leiomyoma 6.7% arthralgia 6.5% headache 6.5% NCT01194258 · Phase 2 · registry result, not featured evidence nasopharyngitis 9.1% supraventricular extrasystoles 6.1% NCT00842361 · Phase 2 · registry result, not featured evidence | f nasopharyngitis 14% upper respiratory tract infection 8% diarrhoea 3.3% NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 15 more resultsupper respiratory tract infection 5.3% NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3 injection site reaction 5.6% NCT03341312 · Phase 1 · registry result, not featured evidence injection site reaction 2.9% NCT03341312 · Phase 1 · registry result, not featured evidence 15 U headache 10% nausea 5% injection site reaction 2.5% NCT03286751 · Phase 1 · registry result, not featured evidence 30 U headache 14.6% injection site reaction 14.6% nausea 7.3% NCT03286751 · Phase 1 · registry result, not featured evidence 7 U headache 15% injection site reaction 2.5% nausea 2.5% NCT03286751 · Phase 1 · registry result, not featured evidence 15 U headache 5.3% vessel puncture site thrombosis 5.3% NCT03305822 · Phase 1 · registry result, not featured evidence 15 U infusion site pain 12% catheter site bruise 8% vessel puncture site bruise 8% NCT03232983 · Phase 1 · registry result, not featured evidence 15 U injection site pain 11.5% application site erythema 7.7% catheter site bruise 7.7% NCT03232983 · Phase 1 · registry result, not featured evidence 15 U catheter site pain 10.7% catheter site swelling 7.1% application site erythema 3.6% NCT03232983 · Phase 1 · registry result, not featured evidence 15 U catheter site bruise 7.7% infusion site erythema 7.7% infusion site swelling 7.7% NCT03232983 · Phase 1 · registry result, not featured evidence headache 6.7% back pain 0% thrombophlebitis 0% NCT02703337 · Phase 1 · registry result, not featured evidence back pain 0% headache 0% thrombophlebitis 0% NCT02703337 · Phase 1 · registry result, not featured evidence · combination thrombophlebitis 6.9% back pain 0% headache 0% NCT02703337 · Phase 1 · registry result, not featured evidence thrombophlebitis 10.3% back pain 0% headache 0% NCT02703337 · Phase 1 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 26 weeks versus 12 weeks.
- ePopulation comparability has not been reviewed for these studies.
- fPopulation comparability has not been reviewed for 14 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
insulin aspart
show 12 more results
show 2 more results
show 2 more results
show 2 more results
show 1 more result
show 2 more results
+ 43 further endpoints in the CSV export.
Insulin lispro (Lyumjev)
+ 6 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin aspart's landscape · Insulin lispro (Lyumjev)'s landscape